Drugs / DSG3-CAART
DSG3-CAART
also known as
Desmoglein 3 Chimeric Autoantibody Receptor T Cells
Cell therapy targets DSG3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04422912 | Sep 2020 → Jan 2029 expected | pemphigus vulgaris | Cabaletta Bio | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSG3-CAART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04422912 ↗ |
| Known as | Desmoglein 3 Chimeric Autoantibody Receptor T Cells | “Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART]” NCT04422912 ↗ |
| Modality | Cell therapy | “investigational cell therapy, DSG3-CAART” NCT04422912 ↗ |
| Route | Intravenous | “Intravenous infusions of DSG3-CAART alone at different doses and different fractionations” NCT04422912 ↗ |
| Target | DSG3 | “Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART]” NCT04422912 ↗ |